A study to check whether addition of Resveratrol is beneficial and safe in patients with Diabetes, Dyslipidemia and Hypertension (who are already on standard therapy)

A Randomized, Open-Label, Active-Control, Phase-IV clinical study evaluating efficacy and safety of Resveratrol as an adjuvant therapy in patients with Diabetes, Dyslipidemia and Hypertension

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/04/008384

Enrollment

180

Registered

2017-04-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Dyslipidemia, Diabetes and hypertension

Interventions

Intervention1: Glimepiride 2mg Plus Oral Resveratrol 1 gram, Atorvastatin 10 mg Plus Oral Resveratrol 1 gram, Telmisartan 20 mg tablet Plus Oral Resveratrol 1 gram: Once daily for 12 months Total dura

Eligibility

Inclusion criteria

Inclusion criteria: Diabetes study: Patients of either gender with known T2DM, aged between 20 and 65 years Patient with borderline blood lipid abnormality and not taking any hypolipidemic agents Patient is on stable monotherapy of Glimeperide 2 mg Patient willing to use Plant based therapy (RESVERATROL) with gold standard therapy in management of their T2DM. Dylipidemia study: Patients with either sex in the age group of 20-65 years suffering from dyslipidemia Patient who are on stable therapy of Atorvastatin 10 mg tablet Patient willing to use Plant based therapy (RESVERATROL) with gold standard therapy (Statin) in management of dyslipidemia. Hypertension study: Patients of either sex, aged 20-65 yrs Patients with Stage I hypertension (SBP 140â??159 mmHg and DBP 90â??99 mmHg) Patients taking monotherapy of Telmisartan 20 mg Patient willing to use Plant based therapy (RESVERATROL) with gold standard therapy (Telmisartan 20 mg) in management of hypertension.

Exclusion criteria

Exclusion criteria: Diabetes study: Patients who are willing to use other antioxidant supplementation rather than RESVERATROL Patients with type 1 diabetes, pregnant women and lactating mothers Patients with dyslipidemia and taking lipid lowering therapy including statin Patients with history of severe heart disease, hepatic and renal dysfunction Patients taking/requiring beta â?? blocker and any drug which produce hyperglycemia or hypoglycemia. Patients with history of allergy with grapes and consume alcohol daily Dylipidemia study: Patients who are willing to use other antioxidant supplementation rather than RESVERATROL Pregnant women and lactating mothers Patients taking/requiring any drug which affect blood lipid level Patients with history of diabetes, severe heart disease, hepatic and renal dysfunction Patients with history of allergy with grapes and consume alcohol daily Hypertension study: Patients who are willing to use other plant based therapy rather than RESVERATROL Patients taking/requiring any drug which affect blood pressure Pregnant women and lactating mothers Patients with history of severe heart disease, hepatic and renal dysfunction Patients with history of allergy with grapes and consume alcohol daily

Design outcomes

Primary

Measure	Time frame
Change in blood sugar level (fasting and fed), lipid profile and SBP and DBP from baseline to end of study visit (12 month)Timepoint: At baseline and 12 month	—

Secondary

Measure	Time frame
Change in blood sugar level (fasting and fed), lipid profile, Hemoglobin A1c and systolic and diastolic blood pressureTimepoint: Baseline, at the end of 3 month, 6 month and 9 month	—

Countries

India

Contacts

Public ContactDr Pranesh Kulkarni

Uka Tarsadia University

rakeshojha0712@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026